It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.
Technology Appraisals Endorsement Process
The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland. The new arrangements are detailed in following circulars, which is effective from 18th December 2013;
NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.
For information, details of the previous arrangement can be found on the following circular;
NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11
The following technology appraisals have been endorsed during 2019/20. Information on technology appraisals endorsed in previous years can be found on the homepage.
NICE TA 622 - Sotagliflozin with insulin for treating type 1 diabetes
NICE TA 623 - Patiromer for treating hyperkalaemia
NICE TA 624 - Peginterferon beta-1a for treating relapsing - remitting multiple sclerosis
NICE TA 617 - Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
NICE TA 619 - Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
NICE TA 620 - Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
- This guidance updates and replaces NICE Technology Appraisal TA381, which was endorsed by the DoH in February 2016.
NICE TA 621 - Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer
NICE TA 614 - Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
NICE TA 615 - Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome
NICE TA 616 - Cladribine for treating relapsing–remitting multiple sclerosis (review of TA493)
- This guidance updates and replaces NICE Technology Appraisal TA493, which was endorsed by the DoH in December 2017.
NICE TA 612 - Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
NICE TA 613 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema in phakic eyes after an inadequate response to previous therapy (part review of TA301)
- This guidance partially updates NICE Technology Appraisal TA301, which was endorsed by the DoH in December 2013.
NICE TA 605 - Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea
NICE TA 606 - Lanadelumab for preventing recurrent attacks of hereditary angioedema
NICE TA 607 - Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
NICE TA 610 - Pentosan polysulfate sodium for treating bladder pain syndrome
NICE TA 611 - Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
NICE TA 599 - Sodium zirconium cyclosilicate for treating hyperkalaemia
NICE TA 600 - Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
NICE TA 604 - Idelalisib for treating refractory follicular lymphoma
NICE TA 592 - Cemiplimab for treating metastatic or locally advanced cutaneous squamous cell carcinoma
NICE TA 593 - Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
NICE TA 595 - Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer
NICE TA 596 - Risankizumab for treating moderate to severe plaque psoriasis
NICE TA 597 - Dapagliflozin with insulin for treating type 1 diabetes
NICE TA 598 - Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
NICE TA 588 - Nusinersen for treating spinal muscular atrophy
NICE TA 589 - Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity
NICE TA 590 - Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis
NICE TA 591 - Letermovir for preventing cytomegalovirus disease after a stem cell transplant
NICE TA 583 - Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
NICE TA 584 - Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
NICE TA 585 - Ocrelizumab for treating primary progressive multiple sclerosis
NICE TA 586 - Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib (partial review of TA171)
- For third- or further-line use, please see NICE Technology Appraisal TA171 - Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies, endorsed by DoH in September 2010.
NICE TA 587 - Lenalidomide plus dexamethasone for previously untreated multiple myeloma
NICE TA 579 - Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
NICE TA 580 - Enzalutamide for hormone-relapsed non-metastatic prostate cancer
NICE TA 581 - Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
NICE TA 573 - Daratumumab with bortezomib and dexamethasone for previously treated multiple
NICE TA 574 - Certolizumab pegol for treating moderate to severe plaque psoriasis
NICE TA 575 - Tildrakizumab for treating moderate to severe plaque psoriasis
NICE TA 577 - Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
NICE TA 578 - Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation
NICE TA 566 - Cochlear implants for children and adults with severe to profound deafness (part review of TA166)
- This guidance updates and replaces NICE Technology Appraisal TA166, which was endorsed by the DoH in November 2011.
NICE TA 565 - Benralizumab for treating severe eosinophilic asthma
NICE TA 567 - Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
NICE TA 569 - Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
NICE TA 571 - Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
NICE TA 572 - Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
NICE TA 559 - Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies